Cargando…

Endostatin and Cystatin C as Potential Biomarkers for Early Prediction of Preeclampsia

[Image: see text] Preeclampsia (PE) is characterized by new onset hypertension and proteinuria. Undoubtedly, some individuals do not fit precisely into this description, and it could be challenging to spot newly developed PE in females who already have hypertension or renal illness. Monitoring the d...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshannag, Fatima, Zaki, Radwa M. M., Hemida, Eman, ElBakry, Mustafa M. M., Noureldeen, Amani F. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652833/
https://www.ncbi.nlm.nih.gov/pubmed/38024766
http://dx.doi.org/10.1021/acsomega.3c05586
_version_ 1785136301137199104
author Alshannag, Fatima
Zaki, Radwa M. M.
Hemida, Eman
ElBakry, Mustafa M. M.
Noureldeen, Amani F. H.
author_facet Alshannag, Fatima
Zaki, Radwa M. M.
Hemida, Eman
ElBakry, Mustafa M. M.
Noureldeen, Amani F. H.
author_sort Alshannag, Fatima
collection PubMed
description [Image: see text] Preeclampsia (PE) is characterized by new onset hypertension and proteinuria. Undoubtedly, some individuals do not fit precisely into this description, and it could be challenging to spot newly developed PE in females who already have hypertension or renal illness. Monitoring the disease’s progression enables the optimization of delivery time while minimizing premature births. The current study explores the diagnostic benefits of serum endostatin and cystatin C in addition to serum and urinary magnesium (Mg) and fractional excretion magnesium (FEMg) for early prediction of PE. The population sample included 82 pregnant women divided into 3 groups: normal pregnancy group served as a control (n = 26), nonpreeclampsia (NPE, n = 34) group included pregnant women with one or more risk factors but did not progress to PE, and pregnant women who developed preeclampsia (PE, n = 22) group. Blood samples were withdrawn at two sampling times: at 12th to 16th and 24th to 26th weeks of gestation. Compared to normal pregnancy, results (X̅ ± SD) indicated a significant increase in serum endostatin in NPE at the first sample (10.78 ± 3.63 ng/mL) and the second sample (28.03 ± 3.79 ng/mL), while cystatin C was at the first sample (0.68 ± 0.06 mg/dL) and the second sample (0.71 ± 0.07 mg/dL). In the PE group, the serum endostatin was 18.86 ± 4.37 ng/mL at the first sampling time and 53.56 ± 9.76 ng/mL for the second sample. Serum cystatin C was also elevated in PE with X̅ ± SD equivalent to 0.73 ± 0.08 and 0.89 ± 0.08 mg/dL at the first and second samples, respectively. On the other hand, serum and urinary Mg in addition to FEMg levels did not significantly differ across the groups under study. Receiver operating characteristic (ROC) curve analysis proved that both endostatin and cystatin C could be good indicators for PE. The findings imply that measuring endostatin and cystatin C at early pregnancy and before progression to PE may be effective in detecting the likelihood of PE. Endostatin could be more precise and sensitive in assessing the probability of PE than cystatin C; however, coupling of the two parameters may be promising.
format Online
Article
Text
id pubmed-10652833
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-106528332023-11-01 Endostatin and Cystatin C as Potential Biomarkers for Early Prediction of Preeclampsia Alshannag, Fatima Zaki, Radwa M. M. Hemida, Eman ElBakry, Mustafa M. M. Noureldeen, Amani F. H. ACS Omega [Image: see text] Preeclampsia (PE) is characterized by new onset hypertension and proteinuria. Undoubtedly, some individuals do not fit precisely into this description, and it could be challenging to spot newly developed PE in females who already have hypertension or renal illness. Monitoring the disease’s progression enables the optimization of delivery time while minimizing premature births. The current study explores the diagnostic benefits of serum endostatin and cystatin C in addition to serum and urinary magnesium (Mg) and fractional excretion magnesium (FEMg) for early prediction of PE. The population sample included 82 pregnant women divided into 3 groups: normal pregnancy group served as a control (n = 26), nonpreeclampsia (NPE, n = 34) group included pregnant women with one or more risk factors but did not progress to PE, and pregnant women who developed preeclampsia (PE, n = 22) group. Blood samples were withdrawn at two sampling times: at 12th to 16th and 24th to 26th weeks of gestation. Compared to normal pregnancy, results (X̅ ± SD) indicated a significant increase in serum endostatin in NPE at the first sample (10.78 ± 3.63 ng/mL) and the second sample (28.03 ± 3.79 ng/mL), while cystatin C was at the first sample (0.68 ± 0.06 mg/dL) and the second sample (0.71 ± 0.07 mg/dL). In the PE group, the serum endostatin was 18.86 ± 4.37 ng/mL at the first sampling time and 53.56 ± 9.76 ng/mL for the second sample. Serum cystatin C was also elevated in PE with X̅ ± SD equivalent to 0.73 ± 0.08 and 0.89 ± 0.08 mg/dL at the first and second samples, respectively. On the other hand, serum and urinary Mg in addition to FEMg levels did not significantly differ across the groups under study. Receiver operating characteristic (ROC) curve analysis proved that both endostatin and cystatin C could be good indicators for PE. The findings imply that measuring endostatin and cystatin C at early pregnancy and before progression to PE may be effective in detecting the likelihood of PE. Endostatin could be more precise and sensitive in assessing the probability of PE than cystatin C; however, coupling of the two parameters may be promising. American Chemical Society 2023-11-01 /pmc/articles/PMC10652833/ /pubmed/38024766 http://dx.doi.org/10.1021/acsomega.3c05586 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Alshannag, Fatima
Zaki, Radwa M. M.
Hemida, Eman
ElBakry, Mustafa M. M.
Noureldeen, Amani F. H.
Endostatin and Cystatin C as Potential Biomarkers for Early Prediction of Preeclampsia
title Endostatin and Cystatin C as Potential Biomarkers for Early Prediction of Preeclampsia
title_full Endostatin and Cystatin C as Potential Biomarkers for Early Prediction of Preeclampsia
title_fullStr Endostatin and Cystatin C as Potential Biomarkers for Early Prediction of Preeclampsia
title_full_unstemmed Endostatin and Cystatin C as Potential Biomarkers for Early Prediction of Preeclampsia
title_short Endostatin and Cystatin C as Potential Biomarkers for Early Prediction of Preeclampsia
title_sort endostatin and cystatin c as potential biomarkers for early prediction of preeclampsia
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652833/
https://www.ncbi.nlm.nih.gov/pubmed/38024766
http://dx.doi.org/10.1021/acsomega.3c05586
work_keys_str_mv AT alshannagfatima endostatinandcystatincaspotentialbiomarkersforearlypredictionofpreeclampsia
AT zakiradwamm endostatinandcystatincaspotentialbiomarkersforearlypredictionofpreeclampsia
AT hemidaeman endostatinandcystatincaspotentialbiomarkersforearlypredictionofpreeclampsia
AT elbakrymustafamm endostatinandcystatincaspotentialbiomarkersforearlypredictionofpreeclampsia
AT noureldeenamanifh endostatinandcystatincaspotentialbiomarkersforearlypredictionofpreeclampsia